Expression and Clinical Significance of CXCR3 in Mantle Cell Lymphoma.
10.7534/j.issn.1009-2137.2019.06.020
- Author:
Ming-Xia ZHU
1
;
Wen-Li WAN
1
;
Yun HONG
1
;
Xiao-Wen ZHU
1
;
Kai HU
1
;
Wei WAN
1
;
Hong-Mei JING
1
;
Xiao-Yan KE
2
Author Information
1. Department of Hematology, Beijing University Third Hospital, Beijing 100191, China.
2. Department of Hematology, Beijing University Third Hospital, Beijing 100191, China,E-mail: xykbysy@163.com.
- Publication Type:Journal Article
- MeSH:
Bone Marrow;
Humans;
Lymphocytes;
Lymphoma, Mantle-Cell;
Prognosis;
Receptors, CXCR3;
metabolism;
Treatment Outcome
- From:
Journal of Experimental Hematology
2019;27(6):1831-1837
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression and clinical significance of chemokine receptor CXCR3 in mantle cell lymphoma (MCL).
METHODS:Flow cytometry was used to detect CXCR3 in lymph nodes and extranodal tissues in 25 newly diagnosed MCL patients. The correlation of the expression of CXCR3 level with clinical features and prognostic factors was analyzed.
RESULTS:Twenty-five tumor submitted specimens all expressed CXCR3 at varied degrees. The expression levels of CXCR3 in lymph nodes (LN) and bone marrow (BM) were higher than those in peripheral blood (PB), and the expression intensity in BM positively correlated with the involved tumor numbers. The absolute values of lymphocytes and hemoglobins level in PB of CXCR3high group were significantly lower than those in CXCR3low group (all P<005). The CXCR3 expression in tumor cells significantly correlated with LDH level, β2-MG level, Ki-67 index, MIPI score and the BM involvement (all P<0.05). But, there was no correlation between the CXCR3 expression and clinical stage, histomorphology (all P>0.05). The overall response rate (ORR) in CXCR3low group was significantly higher than that in CXCR3high group (P=0.001). The expression level of CXCR3 in MCL cells of the effective group was significantly lower than that before treatment (P=0.038), and the CXCR3 expression in the ineffective group was significantly higher than that before treatment (P=0.002). After following up, it was found that the 3-year overall survival (OS) time and progression-free survival (PFS) time in CXCR3high group were significantly shorter than those in CXCR3low group (all P<0.05).
CONCLUSION:The expression level of CXCR3 in MCL closely relates with early metastasis and prognosis. CXCR3 can be used as one of the indicators for clinical efficacy and prognosis evaluation.
